clinical trial · NCT02993731
A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
Sumitomo Pharma America, Inc.·phase3·completed·n = 1,134
Carcinoma, Pancreatic DuctalNapabucasinNab-paclitaxelGemcitabine
brief summary
This is a randomized, open-label, multi-center, phase 3 study of napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine for adult patients with Metastatic Pancreatic Ductal Adenocarcinoma.
started
Dec 1, 2016
primary completion
Mar 1, 2020
completion
Mar 1, 2020
last updated
Nov 15, 2023
official title
A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol